DLA Piper advised Iovance Biotherapeutics, Latham & Watkins advised the underwriters on the transaction. Iovance Biotherapeutics, Inc. (Iovance), a biotechnology company focused on innovating, developing and...
Iovance Biotherapeutics’ US$211 Million Common Stock Offering
Iovance Biotherapeutics’ $200 Million Acquisition of Proleukin
DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2...